Blood disorders
Lymphoma in Lanzhou
兰州 淋巴瘤
4 hospitals in Lanzhou
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Lanzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 16 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 0 papers ledNo open trial led
Lymphoma in every city Lanzhou on the disease page, with the national map
open trials on lymphoma with a hospital in Lanzhou
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Lanzhou as lead sponsor or study site. 0 of them are led by a hospital in Lanzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 4
- Started
- 2026-03
- Posted
- Registry
- NCT07218341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou
- RecruitingSafety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06760039
Age 18 years to 80 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen University; 5 listed hospitals as study sitesBeijing, Fuzhou, Lanzhou, Nanchang, Zhanjiang, Zhuhai
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06854445
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06566586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingOrelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06647940
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Lanzhou, Shantou, Zhuhai
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Started
- 2020-01
- Posted
- Registry
- NCT03936153
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingEvaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07187960
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Lanzhou
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Gansu University of Chinese Medicine甘肃中医药大学附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Affiliated Hospital of Northwest Minzu University甘肃省第二人民医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Child-care Hospital甘肃省妇幼保健院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 13 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Hospital of Lanzhou University兰州大学第一医院 | 3 | 1 | 46 | 45 | 30 | 14 | 39 | none | none | none | none | 3 | 0 | none | 0 | 2 | none | none | none | 7 | none | 1 | none | none | none | none | none | none | none | none | none | 8 | 4 | none | none | none | 1 | 0 | none | 0 | none | 1 | none | none | 0 | none | 0 | none | none | 1 | none | 1 | 0 | none | none | 0 | none | none | none | none | none | |
| Gansu Province Central Hospital甘肃省中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Gansu Provincial Cancer Hospital甘肃省肿瘤医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | 1 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Gansu Provincial Hospital甘肃省人民医院 | none | 2 | none | 76 | 27 | 7 | none | none | none | none | none | 7 | 1 | none | 1 | 3 | none | none | 1 | 7 | none | none | none | none | none | none | none | none | none | none | none | none | 8 | 5 | none | none | 1 | none | none | 0 | none | none | none | 1 | none | none | 0 | none | none | none | none | none | 1 | none | none | none | 1 | none | none | none | none | |
| Lanzhou General Hospital中国人民解放军联勤保障部队第九四〇医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Lanzhou Heavy Ions Hospital兰州市第二人民医院雁滩分院 | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Lanzhou University Second Hospital兰州大学第二医院 | none | 10 | 45 | 108 | 41 | 46 | 171 open | 52 | none | none | 1 | 15 | 5 | 2 | 2 | 12 | none | none | none | 16 | none | none | none | none | none | none | 2 | 2 | none | none | none | 13 | 4 | 9 | 2 | 0 | none | 0 | none | none | none | none | none | 1 | none | none | 2 | 0 | none | none | 0 | 1 | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Lanzhou.
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 46
- Stomach cancer 45
- Lung cancer 30
- Pancreatic cancer 14
- Breast cancer 39
- Osteosarcoma 3
- Gastrointestinal stromal tumour 0
- Ewing sarcoma 0
- Multiple myeloma 2
- Lymphoma 7
- Haemophilia A 1
- Coronary heart disease 8
- Congenital heart disease 4
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 0
- Fabry disease 1
- Behçet disease 0
- IgA nephropathy 0
- Osteogenesis imperfecta 1
- Primary sclerosing cholangitis 1
- Congenital diaphragmatic hernia 0
- Hereditary angioedema 0
- Oesophageal squamous cell carcinoma 2
- Stomach cancer 76
- Lung cancer 27
- Pancreatic cancer 7
- Osteosarcoma 7
- Gastrointestinal stromal tumour 1
- Ewing sarcoma 1
- Multiple myeloma 3
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 7
- Congenital heart disease 8
- Scoliosis 5
- Hepatic echinococcosis 1
- Amyotrophic lateral sclerosis 0
- Duchenne muscular dystrophy 1
- IgA nephropathy 0
- Congenital diaphragmatic hernia 1
- Familial adenomatous polyposis 1
- Oesophageal squamous cell carcinoma 10
- Hepatocellular carcinoma 45
- Stomach cancer 108
- Lung cancer 41
- Pancreatic cancer 46
- Breast cancer 171 open
- Glioma 52
- Chordoma 1
- Osteosarcoma 15
- Gastrointestinal stromal tumour 5
- Neuroblastoma 2
- Ewing sarcoma 2
- Multiple myeloma 12
- Lymphoma 16
- IgG4-related disease 2
- Myasthenia gravis 2
- Coronary heart disease 13
- Congenital heart disease 4
- Scoliosis 9
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 0
- Duchenne muscular dystrophy 1
- IgA nephropathy 2
- Gaucher disease 0
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Lanzhou on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.